BDSX Valuation

Biodesix Inc

Add to Watchlist

Advanced Chart

0.422

-0.012(-2.768%)1D

Overview
Forecast
Valuation
Earnings

BDSX Relative Valuation

BDSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BDSX is overvalued; if below, it's undervalued.

Historical Valuation

Biodesix Inc (BDSX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.67 is considered Undervalued compared with the five-year average of -5.16. The fair price of Biodesix Inc (BDSX) is between 5.41 to 8.25 according to relative valuation methord. Compared to the current price of 0.43 USD , Biodesix Inc is Undervalued By 91.99%.

Relative Value

Fair Zone

5.41-8.25

Current Price：0.43

91.99%

Undervalued

-1.82

Trailing

Forward

-20.83

EV/EBITDA

Biodesix Inc. (BDSX) has a current EV/EBITDA of -20.83. The 5-year average EV/EBITDA is -9.65. The thresholds are as follows: Strongly Undervalued below -26.59, Undervalued between -26.59 and -18.12, Fairly Valued between -1.17 and -18.12, Overvalued between -1.17 and 7.30, and Strongly Overvalued above 7.30. The current Forward EV/EBITDA of -20.83 falls within the Undervalued range.

-4.15

EV/EBIT

Biodesix Inc. (BDSX) has a current EV/EBIT of -4.15. The 5-year average EV/EBIT is -6.87. The thresholds are as follows: Strongly Undervalued below -24.04, Undervalued between -24.04 and -15.45, Fairly Valued between 1.72 and -15.45, Overvalued between 1.72 and 10.30, and Strongly Overvalued above 10.30. The current Forward EV/EBIT of -4.15 falls within the Historic Trend Line -Fairly Valued range.

0.68

Biodesix Inc. (BDSX) has a current PS of 0.68. The 5-year average PS is 3.36. The thresholds are as follows: Strongly Undervalued below -2.12, Undervalued between -2.12 and 0.62, Fairly Valued between 6.09 and 0.62, Overvalued between 6.09 and 8.83, and Strongly Overvalued above 8.83. The current Forward PS of 0.68 falls within the Historic Trend Line -Fairly Valued range.

-2.30

P/OCF

Biodesix Inc. (BDSX) has a current P/OCF of -2.30. The 5-year average P/OCF is -3.02. The thresholds are as follows: Strongly Undervalued below -9.49, Undervalued between -9.49 and -6.26, Fairly Valued between 0.21 and -6.26, Overvalued between 0.21 and 3.45, and Strongly Overvalued above 3.45. The current Forward P/OCF of -2.30 falls within the Historic Trend Line -Fairly Valued range.

-3.09

P/FCF

Biodesix Inc. (BDSX) has a current P/FCF of -3.09. The 5-year average P/FCF is -4.56. The thresholds are as follows: Strongly Undervalued below -13.40, Undervalued between -13.40 and -8.98, Fairly Valued between -0.14 and -8.98, Overvalued between -0.14 and 4.28, and Strongly Overvalued above 4.28. The current Forward P/FCF of -3.09 falls within the Historic Trend Line -Fairly Valued range.

Biodesix Inc (BDSX) has a current Price-to-Book (P/B) ratio of 55.85. Compared to its 3-year average P/B ratio of -2.74 , the current P/B ratio is approximately -2137.69% higher. Relative to its 5-year average P/B ratio of 1.80, the current P/B ratio is about 3008.38% higher. Biodesix Inc (BDSX) has a Forward Free Cash Flow (FCF) yield of approximately -49.77%. Compared to its 3-year average FCF yield of -43.31%, the current FCF yield is approximately 14.91% lower. Relative to its 5-year average FCF yield of -35.21% , the current FCF yield is about 41.35% lower.

54.36

P/B

Median3y

-2.74

Median5y

1.80

-48.96

FCF Yield

Median3y

-43.31

Median5y

-35.21

Competitors Valuation Multiple

The average P/S ratio for BDSX's competitors is 2.11, providing a benchmark for relative valuation. Biodesix Inc Corp (BDSX) exhibits a P/S ratio of 0.68, which is -67.88% above the industry average. Given its robust revenue growth of 11.68%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Radiopharm Theranostics Ltd

Loss

43.36M

EUDA.O

EUDA Health Holdings Ltd

Basel Medical Group Ltd

Loss

37.01M

DYAI.O

Dyadic International Inc

Burning Rock Biotech Ltd

0.64

5.94%

85.59M

Performance Decomposition

Market capitalization of BDSX decreased by 75.64% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 17.93M to 20.02M.

The secondary factor is the Margin Expansion, contributed -4.99%to the performance.

Overall, the performance of BDSX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

11.68%

17.93M → 20.02M

Revenue Growth

-4.99%

-60.30 → -57.29

Margin Expansion

-82.33%

-8.53 → -1.51

P/E Change

-75.64%